Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurjhf/hfr038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors for early mortality following transcatheter edge-to-edge repair of mitral regurgitation.
Cardiovasc Revasc Med
August 2024
Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ, USA. Electronic address:
Background: While transcatheter edge-to-edge repair (TEER) with MitraClip is increasingly used, data on the risk stratification for assessing early mortality after this procedure are scarce.
Objective: This study aimed to assess early mortality and analyze the risk factors of early mortality among patients who underwent TEER.
Methods: Using the all-payer, nationally representative Nationwide Readmissions Database, our study included patients aged 18 years or older who had TEER between January 2017 and November 2020.
Anesthesia challenges and role of transesophageal echocardiography during MitraClip implantation in a patient with end stage heart failure.
Med J Armed Forces India
August 2022
Consultant & Head (Cardiology), Army Hospital (R&R), New Delhi, India.
Patients with dilated cardiomyopathy who have developed mitral valve regurgitation (MR) with reduced left ventricular ejection fraction and are too sick to undergo any surgical repair or replacement are being treated worldwide through catheter-based percutaneous intervention techniques to treat MR like MitraClip system®. There are very few case reports especially from India on anesthetic management during MitraClip device implantation and its specific considerations. We present a case of a 48-year-old male patient, diagnosed as post-myocarditis dilated cardiomyopathy with poor left ventricular ejection fraction (30-35%) and severe MR who underwent mitral clip implantation with fluoroscopy and transesophageal echocardiography guidance under general anesthesia.
View Article and Find Full Text PDFMitral Interventions in Heart Failure.
JACC Heart Fail
August 2023
Cardiovascular Institute at Allegheny Health Network, Pittsburgh, Pennsylvania, USA. Electronic address:
Article Synopsis
- Patients with heart failure and secondary mitral regurgitation (SMR) experience worse health outcomes and quality of life compared to those without SMR.
- Guideline-directed medical therapy remains the primary treatment for SMR, and recent trials on mitral transcatheter edge-to-edge repair have improved insights on which patients might benefit from these procedures with a focus on multidisciplinary care.
- The success of these repairs has led to investigations into their use in populations like end-stage heart failure and cardiogenic shock, alongside ongoing development of new transcatheter devices to enhance treatment options for patients with symptomatic SMR.
Transcatheter edge-to-edge repair of the mitral valve in end stage renal disease patients: mortality fact check.
Ann Transl Med
June 2023
Department of Medicine, Jacobi Medical Center, Bronx, NY, USA.
Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.
Eur Heart J
May 2022
Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, USA.
Aims: Baseline renal dysfunction (RD) adversely impacts outcomes among patients with heart failure (HF) and severe secondary mitral regurgitation (MR). Heart failure and MR, in turn, accelerate progression to end-stage renal disease (ESRD), worsening prognosis. We sought to determine the impact of RD in HF patients with severe MR and the impact of transcatheter mitral valve repair (TMVr) on new-onset ESRD and the need for renal replacement therapy (RRT).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!